Late on Friday Regeneron Pharmaceuticals ($REGN) scored a big win as it announced that the FDA has approved Eylea (aflibercept) for wet, age-related macular degeneration. But after pricing an injection at a slight discount to Roche’s Lucentis–$1,850 t…
Archive for the ‘Aflibercept’ Category
Regeneron finally captures an FDA OK with new eye drug
November 21st, 2011 
John Carroll 
Posted in Aflibercept, Avastin, Blog, Companies, Diagnostics, Eylea, Funding, Genentech, Lucentis, macular degeneration, Medical Devices, Medical Supply, Pharmaceuticals, Regeneron Pharmaceuticals, Roche, Startups, Universities, Videos 
Comments Off